Does treatment with semaglutide increase the risk of colon cancer recurrence?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18147790
Cited by: 0

Abstract

There is no conclusive evidence that semaglutide increases the risk of colon cancer recurrence, with some studies suggesting potential protective effects while others indicate a possible increased incidence of new tumors at high doses.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Diabetes Treatment and Management TGF-β signaling in diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
4 January 2026